Get started
Author

Perry Peters

Observed name: P. Peters
OpenAlex ID: A5036730872
Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day
2012 · Herbert Y. Meltzer, Helio Elkis, et al. · Schizophrenia Research · 97
Randomized clinical trial of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related PTSD and the role of sleep quality in treatment response
2021 · Gregory M. Sullivan, R. Michael Gendreau, et al. · Psychiatry Research · 17
Co-therapy with pimavanserin and risperidone 2 mg provides an improved clinical profile
2008 · H. Meltzer, P. Peters, et al. · Schizophrenia Research · 3
854. Phase 2 Multisite Double-Blind Placebo-Controlled Trial of TNX-102 Sl in Military-Related Posttraumatic Stress Disorder (PTSD): Mediators and Moderators of Treatment Response
2017 · Gregory Sullivan, Judith Gendreau, et al. · Biological Psychiatry · 1
P1.181 Parkinson's Disease Psychosis (PDP): An under-diagnosed condition in spite of its prevalence and impact
2009 · H. Fernandez, F.M. Lio, et al. · Parkinsonism & Related Disorders · 1
P3‐097: Improved nighttime sleep without increased daytime sedation in patients with Parkinson's disease psychosis treated with pimavanserin, a selective 5‐HT2A antagonist
2010 · Hilde Williams, Daun Bahr, et al. · Alzheimer s & Dementia
P3‐140: Decreased caregiver burden among carers of patients with Parkinson's disease psychosis treated with pimavanserin, a selective 5‐HT2A antagonist
2010 · Hilde Williams, Daun Bahr, et al. · Alzheimer s & Dementia
P1.183 Parkinson's Disease Psychosis (PDP): A condition which is undertreated
2009 · F.M. Lio, H. Fernandez, et al. · Parkinsonism & Related Disorders
Works count: 8
Citation count: 119
H-index: 3
I10-index: 2
Year
Topic
Type